Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients

British Journal of Cancer

Volumn 104, Issue 9, 2011, Pages 1377-1383

  Teuffel, O ^a   Amir, E ^b   Alibhai, S ^c   Beyene, J ^d   Sung, L ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

ambulatory care; cost effectiveness; fever; in patients; neutropaenia

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AMBULATORY CARE; ARTICLE; CANCER PATIENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; FEBRILE NEUTROPENIA; HUMAN; MONTE CARLO METHOD; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; ADULT; AGED; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; FEVER; HOSPITAL COSTS; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; NEOPLASMS; NEUTROPENIA; PATIENT DISCHARGE; TIME FACTORS;

EID: 79955471557     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.101     Document Type: Article

References (38)

1. Bala MV, Zarkin GA (2000) Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ 9: 177-180 (Pubitemid 30148164)
2. Bennett CL, Calhoun EA (2007) Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 12: 478-483 (Pubitemid 46698725)
3. Birch S, Gafni A (2006) Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 24: 1121-1131 (Pubitemid 44683368)
4. Brown RE, Hutton J, Burrell A (2001) Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19: 1091-1102 (Pubitemid 33135697)
5. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103: 2629-2635 (Pubitemid 40800544)
6. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford University Press: New York
7. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26: 606-611 (Pubitemid 351264355)
8. Escalante CP, Weiser MA, Manzullo E, Benjamin R, Rivera E, Lam T, Ho V, Valdres R, Lee EL, Badrina N, Fernandez S, DeJesus Y, Rolston K (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12: 657-662 (Pubitemid 39280317)
9. Havrilesky LJ, Broadwater G, Davis DM, Nolte KC, Barnett JC, Myers ER, Kulasingam S (2009) Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol 113: 216-220
10. Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, Gemez C, Ruiz A, Garcia-Carbonero R, Cortes-Funes H (1999) Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 85: 213-219 (Pubitemid 29031377)
11. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751 (Pubitemid 34194843)
12. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study (see comment). Br J Cancer 89: 43-49 (Pubitemid 36897933)
13. Kamboj M, Sepkowitz KA (2009) Nosocomial infections in patients with cancer. Lancet Oncol 10: 589-597
14. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24: 4129-4134 (Pubitemid 46622289)
15. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3051 (Pubitemid 30644129)
16. Lathia N (2008) Evaluation of direct medical costs, lost productivity, health utility and quality of life in patients hospitalized for febrile neutropenia. Master of Science University of Toronto: Toronto, Canada
17. Lathia N, Mittmann N, DeAngelis C, Knowles S, Cheung M, Piliotis E, Shear N, Walker S (2010) Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116: 742-748
18. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW (2007) Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Invest 27: 381-396 (Pubitemid 46873100)
19. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial [see comment]. Am J Med 98: 224-231
20. Minotti V, Gentile G, Bucaneve G, Iori AP, Micozzi A, Cavicchi F, Barbabietola G, Landonio G, Menichetti F, Martino P, Del Favero A (1999) Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 7: 134-139 (Pubitemid 29187560)
21. Patrick DL, Bush JW, Chen MM (1973) Methods for measuring levels of well-being for a health status index. Health Serv Res 8: 228-245
22. Rapoport BL, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, Iglesias L, Stein G, Charnas R, Heitlinger E, Handschin J (1999) Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs standard in-patient care. Chemotherapy 45: 466-476 (Pubitemid 29531418)
23. Renwick W, Pettengell R, Green M (2009) Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs 23: 175-186
24. Rolston KVI, Manzullo EF, Elting LS, Frisbee-Hume SE, McMahon L, Theriault RL, Patel S, Benjamin RS (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 106: 2489-2494 (Pubitemid 43787675)
25. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71: 3640-3646 (Pubitemid 23152677)
26. Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16: 1017-1023
27. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6: 122-174
28. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19: 422-437
29. Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 276: 1339-1341 (Pubitemid 26346934)
30. Simon A, Ammann RA, Bode U, Fleischhack G, Wenchel HM, Schwamborn D, Gravou C, Schlegel PG, Rutkowski S, Dannenberg C, Korholz D, Laws HJ, Kramer MH (2008) Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 8: 70
31. Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH (2000) Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 21: 592-596
32. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12: 107-114 (Pubitemid 24020628)
33. Tamura K (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26(Suppl 2): S123-S127; discussion S133-40 (Pubitemid 41606722)
34. Teuffel O, Ethier MC, Alibhai SMH, Beyene J, Sung L (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22; E-pub ahead of print 1 March 2011
35. Torrance GW (1976) Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 10: 129-136
36. Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40: 593-603
37. Torrance GW, Feeny D, Furlong W (2001) Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 21: 329-334 (Pubitemid 32652496)
38. VonNeumann J, Morgenstern O (1953) Theory of Games and Economic Behaviour, 3rd edn. Princeton: New York